{"id":991796,"date":"2026-08-06T22:44:57","date_gmt":"2026-08-07T02:44:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-reports-second-quarter-2026-financial-results-and-provides-business-update\/"},"modified":"2026-08-06T22:44:57","modified_gmt":"2026-08-07T02:44:57","slug":"ardelyx-reports-second-quarter-2026-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-reports-second-quarter-2026-financial-results-and-provides-business-update\/","title":{"rendered":"Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year<\/em>\n <\/p>\n

\n IBSRELA <\/em>
\n Q2<\/em>
\n 2026<\/em>
\n revenue growth of <\/em>
\n 33%<\/em>
\n year-over-year to <\/em>
\n $86.2\u00a0million<\/em>\n <\/p>\n

\n XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9\u00a0million<\/em>\n <\/p>\n

\n Strong financial position with <\/em>
\n $281.8\u00a0million<\/em>
\n in cash, cash equivalents and investments as of <\/em>
\n June\u00a030, 2026<\/em>\n <\/p>\n

\n Revising FY 2026 and long-term guidance<\/em>\n <\/p>\n

\n Conference call scheduled for <\/em>
\n 4:30 PM <\/em>
\n Eastern Time<\/em>\n <\/p>\n

WALTHAM, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) — Ardelyx Inc. (Nasdaq: ARDX), (\u201cArdelyx\u201d or the \u201cCompany\u201d) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the second quarter ended June\u00a030, 2026, and provided a business update.<\/p>\n

\u201cIn the second quarter of 2026, we delivered combined revenue of $118 million, up 31% year over year, the largest quarterly revenue in our Company\u2019s history,\u201d said Mike Raab, President and Chief Executive Officer of Ardelyx. \u201cXPHOZAH had an excellent quarter, reinforcing the strength of our commercial foundation. The demand for IBSRELA was strong despite revenues below our expectations resulting from significantly increased utilization management processes from payors that we are actively addressing. The underlying fundamentals of our business remain robust and considering the recent market dynamics, we are updating our full year and future growth outlook. We are generating significant revenue, and we are moving towards profitability in 2027. We are a high-growth company with the demonstrated ability to effectively manage through external challenges, and I have full confidence in our team\u2019s ability to execute. Our commitment to patients and to creating long-term shareholder value remains steadfast.\u201d<\/p>\n

\n
\n Product Revenue<\/u>
\n <\/strong>
\n
Revenue for IBSRELA\u00ae<\/sup> (tenapanor) during the second quarter of 2026 was $86.2\u00a0million, reflecting year-over-year growth of 33%. The growth was driven by increases in refills and total prescriptions, reaching the highest demand quarter to date.<\/p>\n

Revenue for XPHOZAH\u00ae<\/sup> (tenapanor) during the second quarter of 2026 was $31.9\u00a0million, reflecting year-over-year growth of 27%. The growth was driven by a strong increase in total writers, new and refill prescriptions, and total prescriptions.<\/p>\n

\n
\n Updated Financial Guidance and Outlook<\/u>
\n <\/strong>\n <\/p>\n